IMC Chicago
VKTX icon

IMC Chicago’s Viking Therapeutics VKTX Stock Holding History

IMC Chicago’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.83M Buy
175,100
+70,700
+68% +$2.28M ﹤0.01% 1846
2026
Q1 		$3.4M Buy
104,400
+24,300
+30% +$781K ﹤0.01% 2119
2025
Q4 		$2.82M Sell
80,100
-38,100
-32% -$1.35M ﹤0.01% 2156
2025
Q3 		$3.11M Buy
118,200
+67,000
+131% +$2M ﹤0.01% 1935
2025
Q2 		$1.36M Buy
+51,200
New +$1.35M ﹤0.01% 2277

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

IMC Chicago's VKTX Position: Q2 2026 in Review

IMC Chicago reduced its Viking Therapeutics (VKTX) stake by 15% in Q2 2026, selling an estimated $149K and leaving 26,811 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3808.

IMC Chicago first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • IMC Chicago held 26,811 shares of Viking Therapeutics worth $1.05M as of Q2 2026.
  • IMC Chicago sold 4,615 Viking Therapeutics shares in Q2 2026, an estimated $149K.
  • Viking Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #3808 holding.
  • IMC Chicago first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.